false
0001130166
0001130166
2023-11-13
2023-11-13
0001130166
us-gaap:CommonStockMember
2023-11-13
2023-11-13
0001130166
us-gaap:PreferredStockMember
2023-11-13
2023-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange
Act of 1934
Date of Report (Date
of earliest event reported): November 13, 2023
CYCLACEL
PHARMACEUTICALS, INC.
(Exact name of registrant
as specified in its charter)
Delaware |
|
0-50626 |
|
91-1707622 |
(State
or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS
Employer
Identification No.) |
200
Connell Drive, Suite 1500
Berkeley
Heights, NJ 07922
(Address of principal
executive offices and zip code)
Registrant’s telephone
number, including area code: (908) 517-7330
(Former Name or Former
Address, if Changed Since Last Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered
|
Common
Stock, par value $0.001 per share |
CYCC |
The Nasdaq
Capital Market |
Preferred
Stock, $0.001 par value |
CYCCP |
The Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 |
Results of Operations and Financial Condition. |
The information set forth
under this “Item 2.02. Results of Operations and Financial Condition,” including the exhibit attached hereto, shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference
in such filing.
Attached as Exhibit 99.1 is
a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the “Company”), dated November 13, 2023, announcing certain
financial results for the third quarter ended September 30, 2023.
The Company will conduct a
conference call to review its financial results on November 13, 2023, at 4:30 p.m., Eastern Time.
Item 9.01 | Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
CYCLACEL PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Paul McBarron |
|
Name: |
Paul McBarron |
|
Title: |
Executive Vice President-Finance, |
|
|
Chief Financial Officer and Chief Operating Officer |
|
Date: November 13, 2023
Exhibit 99.1
|
Cyclacel Pharmaceuticals, Inc. |
Cyclacel
Pharmaceuticals Reports THIRD quarter financial results
and
provides business update
- Cyclacel
Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism
Update for Oral Plogosertib -
- Management to Host Conference Call at 4:30
pm ET Today -
BERKELEY HEIGHTS, NJ, November 13, 2023 -
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a
biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today third quarter financial
results and provided a business update.
“Fadraciclib continues to show good tolerability
and anticancer activity as a single agent,” said Spiro Rombotis, President and Chief Executive Officer. “After analyzing the
genomic profile of several Phase 1 patients with clinical benefit, we have identified mutational and molecular patterns that may be predictive
of clinical activity across broad cancer types. If confirmed, these findings may be relevant in the upcoming Phase 2 part of our 065-101
study. In our Phase 1/2 study of plogosertib good tolerability and anticancer activity as a single agent has been observed in multiple
patients with various solid tumors. Preclinical data continues to suggest that plogosertib may work through an epigenetic mechanism and
that certain mutational biomarkers may identify patients with sensitive tumors. We look forward to presenting data from these two programs
and their mechanisms in the coming months.”
“In the 065-101 study of oral fadraciclib,
our CDK2/9 inhibitor, as monotherapy, we are completing dose escalation level 6A with six patients and expect to select the recommended
Phase 2 dosing schedule shortly. We are encouraged by the observations of anticancer activity and the related patient genomic profiles,”
said Mark Kirschbaum, M.D., Chief Medical Officer. “We believe that fadraciclib’s inhibition of CDK2 and CDK9 may be superior
to either CDK2 or CDK9 alone. Importantly, we have been able to give fadraciclib orally with repeat dosing which has led to transient
suppression of anti-apoptosis proteins without hematological toxicity. In the 140-101 study of oral plogosertib, our PLK1 inhibitor as
a single agent, we are recruiting patients at dose level 5. The anticancer activity observed at low levels of continuous exposure may
be due to plogosertib’s novel epigenetic mechanism which we are continuing to investigate. If confirmed, we intend to design clinical
studies that could exploit these findings.”
Key Milestones
| · | Report final data from dose escalation stage and RP2D determination from the 065-101 study of oral fadraciclib
in patients with advanced solid tumors and lymphoma |
| · | First patient dosed with oral fadraciclib in Phase 2 proof-of-concept stage of 065-101 study in patients
with advanced solid tumors and lymphoma |
| · | Report Phase 1 data from 140-101 study of oral plogosertib in patients with advanced solid tumors and lymphoma |
| · | Disclose novel epigenetic mechanism of action of plogosertib |
Financial
Highlights
As of September 30, 2023,
cash equivalents totaled $5.9 million, compared to $18.3 million as of December 31, 2022. Net cash used in operating activities was $12.2
million for the nine months ended September 30, 2023 compared to $15.7 million for the same period of 2022. The Company estimates
that its available cash will fund currently planned programs through the end of 2023. The operating plan includes discretionary
expenditures, which if not incurred could extend cash runway into the second quarter of 2024.
Research and development
(R&D) expenses were $5.2 million for the three months ended September 30, 2023, as compared to $4.4 million for the same period in
2022. R&D expenses relating to fadraciclib were $3.6 million for the three months ended September 30, 2023, as compared to $2.5 million
for the same period in 2022 due to due to increased costs associated with manufacture scale up and introduction of the tablet form. R&D
expenses related to plogosertib were $1.5 million for the three months ended September 30, 2023, as compared to $1.7 million for the same
period in 2022.
General and administrative
expenses for the three months ended September 30, 2023 were $1.6 million, as compared to $2.1 million for the same period in 2022 due
to non-recurring professional fees of $0.4 million in the prior period.
Total other income, net,
for the three months ended September 30, 2023, was $0.1 million compared to an income of $0.4 million for the same period of the previous
year.
United Kingdom research
& development tax credits for the three months ended September 30, 2023 were $0.6 million compared to $1.0 million for the same period
of the previous year due to taxation legislative changes that took effect in April 2023 and reduced the amount of tax credit that could
be claimed. Research & development tax credits are directly correlated to qualifying research and development expenditure.
Net loss for the three months
ended September 30, 2023, was $6.1 million, compared to $5.1 million for the same period in 2022.
Conference
call information:
Call: (800)
245-3047 / international call: (203) 518-9765
Archive:
(800) 688-7036 / international archive: (402) 220-1346
Code
for live and archived conference call is CYCCQ323. Webcast link
For
the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com.
The webcast will be archived for 90 days and the audio replay for 7 days.
About
Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based
on cell cycle, transcriptional regulation, epigenetics and mitosis biology. The transcriptional regulation program is evaluating fadraciclib,
a CDK2/9 inhibitor, and the epigenetic/anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological
malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates
addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Forward-looking
Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could
cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization
of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future
research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include
the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy
in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its
product candidates, the risks associated with reliance on outside financing to meet capital requirements, the potential effects of the
COVID-19 pandemic, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization
of product candidates. You are urged to consider statements that include the words "may," "will," "would,"
"could," "should," "believes," "estimates," "projects," "potential," "expects,"
"plans," "anticipates," "intends," "continues," "forecast," "designed," "goal,"
or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the
risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings
we file with the Securities and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.
Contacts
Company: |
Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
Investor Relations: |
Grace Kim, IR@cyclacel.com |
© Copyright 2023 Cyclacel Pharmaceuticals, Inc.
All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
SOURCE: Cyclacel Pharmaceuticals, Inc.
CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)
(In $000s, except share and per share amounts)
| |
Three Months Ended | |
| |
September 30, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Revenues | |
$ | 16 | | |
$ | - | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
Research and development | |
| 5,236 | | |
| 4,413 | |
General and administrative | |
| 1,625 | | |
| 2,054 | |
Total operating expenses | |
| 6,861 | | |
| 6,467 | |
Operating loss | |
| (6,845 | ) | |
| (6,467 | ) |
Other income (expense): | |
| | | |
| | |
Foreign exchange gains (losses) | |
| 104 | | |
| 276 | |
Interest income | |
| 50 | | |
| 67 | |
Other income, net | |
| (8 | ) | |
| 14 | |
Total other income (expense), net | |
| 146 | | |
| 357 | |
Loss before taxes | |
| (6,699 | ) | |
| (6,110 | ) |
Income tax benefit | |
| 602 | | |
| 1,014 | |
Net loss | |
| (6,097 | ) | |
| (5,096 | ) |
Dividend on convertible exchangeable preferred shares | |
| (50 | ) | |
| (50 | ) |
Net loss applicable to common shareholders | |
$ | (6,147 | ) | |
$ | (5,146 | ) |
Basic and diluted earnings per common share: | |
| | | |
| | |
Net loss per share – basic and diluted | |
$ | (0.49 | ) | |
$ | (0.42 | ) |
Weighted average common shares outstanding | |
| 12,642,822 | | |
| 12,314,679 | |
CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEET
(In $000s, except share, per share, and liquidation
preference amounts)
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 5,944 | | |
$ | 18,345 | |
Prepaid expenses and other current assets | |
| 5,104 | | |
| 6,066 | |
Total current assets | |
| 11,048 | | |
| 24,411 | |
| |
| | | |
| | |
Property and equipment, net | |
| 16 | | |
| 32 | |
Right-of-use lease asset | |
| 109 | | |
| 142 | |
Non-current deposits | |
| 1,259 | | |
| 3,465 | |
Total assets | |
$ | 12,432 | | |
$ | 28,050 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 1,571 | | |
$ | 2,561 | |
Accrued and other current liabilities | |
| 6,458 | | |
| 4,831 | |
Total current liabilities | |
| 8,029 | | |
| 7,392 | |
Lease liability | |
| 52 | | |
| 106 | |
Total liabilities | |
| 8,081 | | |
| 7,498 | |
| |
| | | |
| | |
Redeemable common stock | |
| - | | |
| 4,494 | |
| |
| | | |
| | |
Stockholders’ equity | |
| 4,351 | | |
| 16,058 | |
Total liabilities and stockholders’ equity | |
$ | 12,432 | | |
$ | 28,050 | |
v3.23.3
Cover
|
Nov. 13, 2023 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 13, 2023
|
Entity File Number |
0-50626
|
Entity Registrant Name |
CYCLACEL
PHARMACEUTICALS, INC.
|
Entity Central Index Key |
0001130166
|
Entity Tax Identification Number |
91-1707622
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
200
Connell Drive
|
Entity Address, Address Line Two |
Suite 1500
|
Entity Address, City or Town |
Berkeley
Heights
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
07922
|
City Area Code |
908
|
Local Phone Number |
517-7330
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Common Stock [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Common
Stock, par value $0.001 per share
|
Trading Symbol |
CYCC
|
Security Exchange Name |
NASDAQ
|
Preferred Stock [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Preferred
Stock, $0.001 par value
|
Trading Symbol |
CYCCP
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Cyclacel Pharmaceuticals (NASDAQ:CYCCP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 5월(5) 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCCP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024